A Surprising Trial: Opioids Show No Clear Advantage for Cancer-Related Exertional Dyspnoea
A new double-blind, placebo-controlled, randomised clinical trial published in *Thorax* challenges the efficacy of daily opioid therapy for managing exertional dyspnoea in cancer patients. The study compared prophylactic fentanyl buccal tablet (FBT), oral morphine, and a placebo over 14 days in opioid-tolerant patients. The primary outcome, change in dyspnoea intensity during shuttle walk tests, showed a significant decrease over time in all three groups, with no statistically significant difference between the active opioid treatments and the placebo. Similarly, while walking distance improved for all participants, there was no treatment-specific benefit. This research highlights the complex role of expectation and habituation in dyspnoea perception and suggests that the routine use of opioids for this specific indication may require re-evaluation, especially given the ongoing focus on opioid stewardship and multimodal analgesia in palliative care.
Study Significance: For clinicians in pain medicine and palliative care, this study provides critical data for refining opioid therapy protocols. It underscores the importance of distinguishing between different types of refractory symptoms and reinforces the need for robust evidence before expanding opioid indications. The findings support a continued shift towards comprehensive, non-opioid-centric strategies for managing complex symptoms like exertional dyspnoea, aligning with broader goals of functional restoration and minimizing medication-related harms.
Source →Stay curious. Stay informed — with Science Briefing.
Always double check the original article for accuracy.
